Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing for the treatment of genetic cardiovascular diseases
Company stage: Pre-clinical
Diseases: Heterozygous familial hypercholesterolemia, familial hypercholesterolemia
Genome editing technology: Base editing, CRISPR-Cas9, CRISPR-Cas12a
Funding stage: Public (NASDAQ:VERV)
Location: Cambridge, MA, USA
Partners: Beam Therapeutics
Verve Therapeutics is a pre-clinical stage gene-editing company that focuses on developing novel therapies for genetic cardiovascular diseases. The company holds multiple licenses from The Broad Institute and has also licensed base-editing technology from Beam Therapeutics. The company is initially focusing on PCSK9 and ANGPTL3 as targets.